Medpace CEO sells 24,741 shares around $621
Medpace’s CEO reported selling 24,741 MEDP shares in open-market limit-order trades while retaining a large indirect stake via Medpace Investors, LLC.
Rhea-AI Filing Summary
Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported open-market sales of Medpace common stock. On September 15, 2026, he sold 15,971 shares at a weighted average price of $620.84, and on September 16, 2026, he sold 8,770 shares at a weighted average price of $621.29, for total reported sales of 24,741 shares.
The trades were effected pursuant to a limit order during an open window period. Troendle also reports 4,733,019 shares of Medpace common stock held indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unitholder; he may be deemed to beneficially own those securities but disclaims beneficial ownership except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 24,741 shares
Net Sell
3 txns
Insider
Troendle August J.
Role
President & CEO
Sold
24,741 shs ($15.36M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F3 | 8,770 | $621.29 | $5.45M |
| Sale | Common Stock F1, F2 | 15,971 | $620.84 | $9.92M |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 515,153 shares (Direct);
Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)
Footnotes (4)
- F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
- F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $622.84. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $620.00 to $623.90. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Key Figures
Shares sold on September 15, 2026: 15,971 shares
Weighted average price on September 15, 2026 sale: $620.84 per share
Shares sold on September 16, 2026: 8,770 shares
+3 more
6 metrics
Shares sold on September 15, 2026
15,971 shares
Open-market sale of Medpace common stock by August J. Troendle
Weighted average price on September 15, 2026 sale
$620.84 per share
Multiple transactions ranging from $620.00 to $622.84
Shares sold on September 16, 2026
8,770 shares
Open-market sale of Medpace common stock by August J. Troendle
Weighted average price on September 16, 2026 sale
$621.29 per share
Multiple transactions ranging from $620.00 to $623.90
Total shares sold in reported transactions
24,741 shares
Combined sales on September 15–16, 2026
Indirectly held shares via Medpace Investors, LLC
4,733,019 shares
Common stock of Medpace reported as indirectly owned after transactions
Key Terms
limit order, weighted average price, indirectly beneficially own, pecuniary interest
4 terms
limit order financial
"transactions were effected pursuant to a limit order placed by the Reporting Person"
A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.
weighted average price financial
"The reported price is a weighted average price. These shares were sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirectly beneficially own financial
"may be deemed to indirectly beneficially own the securities of the Issuer"
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did MEDP’s CEO report on this Form 4?
August J. Troendle reported two open-market sales of Medpace common stock: 15,971 shares on September 15, 2026 and 8,770 shares on September 16, 2026, for a total of 24,741 shares sold.
Were the MEDP CEO’s recent stock sales made under a Rule 10b5-1 trading plan?
No Rule 10b5-1 plan is reported. A footnote states the transactions were effected pursuant to a limit order placed by the reporting person during an open window period, without identifying them as made under a trading plan.
What is the nature of August J. Troendle’s indirect MEDP ownership through Medpace Investors, LLC?
August J. Troendle is the sole manager and controlling unitholder of Medpace Investors, LLC and has sole voting and investment control over its Medpace shares. He disclaims beneficial ownership of those securities except to the extent of his pecuniary interest in them.
AI-generated analysis. How Rhea-AI works. Not financial advice.
